Johnson & Johnson Basic Shares Outstanding 2010-2024 | JNJ

Johnson & Johnson annual/quarterly basic shares outstanding history and growth rate from 2010 to 2024. Basic shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares.
  • Johnson & Johnson basic shares outstanding for the quarter ending September 30, 2024 were $2.407B, a 4.59% decline year-over-year.
  • Johnson & Johnson basic shares outstanding for the twelve months ending September 30, 2024 were $9.756B, a 5.76% decline year-over-year.
  • Johnson & Johnson annual basic shares outstanding for 2023 were $2.534B, a 3.49% decline from 2022.
  • Johnson & Johnson annual basic shares outstanding for 2022 were $2.625B, a 0.26% decline from 2021.
  • Johnson & Johnson annual basic shares outstanding for 2021 were $2.632B, a 0.03% decline from 2020.
Johnson & Johnson Annual Basic Shares Outstanding
(Millions of US $)
2023 $2,534
2022 $2,625
2021 $2,632
2020 $2,633
2019 $2,645
2018 $2,682
2017 $2,692
2016 $2,737
2015 $2,772
2014 $2,815
2013 $2,809
2012 $2,753
2011 $2,736
2010 $2,751
2009 $2,760
Johnson & Johnson Quarterly Basic Shares Outstanding
(Millions of US $)
2024-09-30 $2,407
2024-06-30 $2,407
2024-03-31 $2,408
2023-12-31 $2,534
2023-09-30 $2,523
2023-06-30 $2,598
2023-03-31 $2,606
2022-12-31 $2,625
2022-09-30 $2,628
2022-06-30 $2,630
2022-03-31 $2,629
2021-12-31 $2,632
2021-09-30 $2,633
2021-06-30 $2,633
2021-03-31 $2,632
2020-12-31 $2,633
2020-09-30 $2,633
2020-06-30 $2,633
2020-03-31 $2,634
2019-12-31 $2,645
2019-09-30 $2,635
2019-06-30 $2,653
2019-03-31 $2,661
2018-12-31 $2,682
2018-09-30 $2,683
2018-06-30 $2,682
2018-03-31 $2,682
2017-12-31 $2,692
2017-09-30 $2,685
2017-06-30 $2,692
2017-03-31 $2,707
2016-12-31 $2,737
2016-09-30 $2,732
2016-06-30 $2,745
2016-03-31 $2,757
2015-12-31 $2,772
2015-09-30 $2,768
2015-06-30 $2,772
2015-03-31 $2,783
2014-12-31 $2,815
2014-09-30 $2,814
2014-06-30 $2,826
2014-03-31 $2,827
2013-12-31 $2,809
2013-09-30 $2,818
2013-06-30 $2,810
2013-03-31 $2,790
2012-12-31 $2,753
2012-09-30 $2,757
2012-06-30 $2,747
2012-03-31 $2,737
2011-12-31 $2,736
2011-09-30 $2,737
2011-06-30 $2,741
2011-03-31 $2,738
2010-12-31 $2,751
2010-09-30 $2,752
2010-06-30 $2,757
2010-03-31 $2,755
2009-12-31 $2,760
2009-09-30 $2,756
2009-06-30 $2,756
2009-03-31 $2,766
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $375.059B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $716.733B 74.24
Novo Nordisk (NVO) Denmark $469.216B 33.84
AbbVie (ABBV) United States $312.890B 16.47
Merck (MRK) United States $255.898B 17.00
Novartis AG (NVS) Switzerland $211.636B 14.07
AstraZeneca (AZN) United Kingdom $205.880B 17.52
Pfizer (PFE) United States $148.305B 10.14
Sanofi (SNY) $122.704B 11.11
Innoviva (INVA) United States $1.201B 9.99